| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI can help improve the quality of the result and provide, usually, accurate information to aid with diagnostic accuracy. |
Article from National Institutes of Health. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy is the ability to understand, evaluate, and use AI technologies effectively and responsibly. |
IBM. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
Other options influence the acceptability of AI, however, the colour of the AI machines do not. |
ScienceDirect.com |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence could play a part in Healthcare professionals' decisions to use AI, either to public pressure or other factors. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
AI usage could be unreliable, and they could replace healthcare professionals in the far future. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Ensuring AI systems have high algorithmic performance |
|
Other options do influence the acceptability of AI, but ensuring that AI systems have high performance influence more in my opinion. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
According to an article on AI acceptability factors, the "system usage" category includes aspects like the perceived value proposition, the user's self-efficacy (belief in their ability to use the system), the burden of using the system, and its workflow integration. |
ScienceDirect.com |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethical considerations significantly impact AI acceptability among healthcare professionals, acting as a primary driver of trust, confidence, and willingness to use these new tools in clinical practice. |
ScienceDirect.com
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
Future studies on AI acceptability should emphasize naturalistic methods that capture real-world deployment contexts rather than solely relying on self-reported data to better understand how people interact with AI. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Lost dopamine neurons are the source of motor systems in Parkinson's disease, replacing the lost dopamine neurons with new ones are an effective treatment, thus fixing the problem. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
Rats, specifically immunodeficient nude rats, were used to test the STEM-PD product for safety and efficacy. These studies demonstrated that the cells were safe, did not cause tumor formation, and had no adverse effects. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
3 months |
|
The duration of preclinical safety studies in rats typically varies depending on the type of study and regulatory requirements, but usually three months to six months. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The STEM-PD clinical trial mentioned is a Phase I/IIa study. It is investigating a stem cell-based therapy for Parkinson's Disease. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured using a process that starts with human embryonic stem cells, which are differentiated into dopaminergic progenitor cells under strict Good Manufacturing Practice (GMP)-compliant protocols. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The transplanted cells were able to reverse motor deficits in the animal models of Parkinson's disease. |
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
|
An article about Preclinical safety, quality from Cell Press. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
In the manufacturing process of STEM-PD, the growth factors FGF8b (fibroblast growth factor 8b) and SHH (sonic hedgehog) play a crucial role in the differentiation of pluripotent stem cells into midbrain dopaminergic (mDA) progenitor cells. |
National Institutes of Health (.gov) |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
|
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|